Education And Debate

Patients' readiness to start highly active antiretroviral treatment for HIV

BMJ 2005; 331 doi: http://dx.doi.org/10.1136/bmj.331.7519.772 (Published 29 September 2005) Cite this as: BMJ 2005;331:772
  1. Hirut T Gebrekristos, research fellow (hgebrekr{at}jhsph.edu)1,
  2. Koleka P Mlisana, project director1,
  3. Quarraisha Abdool Karim, associate professor1
  1. 1 Centre for AIDS Programme of Research in South Africa (CAPRISA), Nelson R Mandela, School of Medicine, Durban, South Africa
  1. Correspondence to: H T Gebrekristos

    Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes

    Introduction

    Initiatives to increase access to antiretroviral treatment in resource constrained settings are growing, but the scale and magnitude of the HIV epidemic in these settings raises a number of operational and ethical challenges. Most people infected with HIV are unaware of their status, and people who are aware of their status fear stigmatisation and discrimination. Key themes about access to treatment include who gets treatment, when is the best time to start treatment, and how to ensure therapeutic success.

    Numerous guidelines for treatment have been developed nationally and internationally. One concern is how initiation of antiretroviral treatment should relate to patients' readiness and commitment. Although patients' readiness is emphasised as a requirement for starting treatment in several guidelines,14 the guidelines are neither clear nor in consensus about what constitutes readiness and how this readiness should be assessed. Given this ambiguity, readiness may be used to ration resources, particularly in resource poor settings, in which access to antiretrovirals is currently gaining support. The potential of using readiness to improve HIV prevention and care outcomes, however, mandates that we closely examine the use of readiness for starting highly active antiretroviral treatment (HAART).

    Studies about assessing patients' readiness for starting HAART or the impact of this on therapeutic success are few. One small study found that lack of readiness resulted in interrupted treatment and risky sexual behaviour; therefore, readiness for treatment may help care givers to make decisions about when to start treatment with antiretrovirals for each patient.5 The potential importance of treatment readiness for therapeutic success is why a more structured and systematic approach to evaluating readiness is needed. In addition, a systematic evaluation of the use of treatment readiness becomes particularly important in settings where “readiness” may be misused to ration resources. Rigorously collected data will be critical in shaping appropriate interventions that go beyond anecdotal notions that readiness is important in determining when to start HAART.

    Clinical indicators have been central to debates on when to initiate HAART, where CD4 cell count is a key determining factor.69 By incorporating a compulsory drug readiness programme into decisions on starting treatment, the South African government's HAART rollout plan expands this debate.10 The South African plan is fairly detailed and specific in requiring education on HIV/AIDS, positive living, opportunistic infections, care and treatment for HIV/AIDS, HAART side effects, and the importance of treatment adherence. Although early in its implementation, the South African HAART rollout plan not only expands the debate on when to initiate therapy, but may also provide an opportunity to understand and evaluate the benefit of treatment readiness for decisions on HAART initiation.

    What are possible ways of understanding and ascertaining patients' readiness for starting HAART? Intuitively, we would expect there to be a range of levels for readiness depending, among other things, on disease state, knowledge and understanding of anti-retrovirals, levels of stigma and discrimination, sex, existing support structures, and motivation. Given the complex set of factors that are likely to influence readiness, what minimum level of readiness should distinguish between decisions to start or delay treatment? Using the South African HAART rollout plan as a point of departure, we present a framework for how readiness may be understood and suggest a possible method that may help in measuring readiness.



    Embedded Image

    Patients waiting at the doctors clinic at the Leratong Hospital in Krugersdorp

    Credit: JORGEN SCHYTTE/STILL PICTURES

    What constitutes adequate readiness to start HAART?

    One way of considering and distinguishing between different levels of treatment readiness is to think in terms of variations of health literacy, including three broad categories—basic, functional, and critical literacy.11 12 Within this context, readiness can range from knowledge of basic information about antiretroviral treatment to a more comprehensive approach that empowers patients not only to understand the fundamentals involved in participating in treatment but also includes the social skills and capacity to effectively access other pertinent health services and maintain good health. Using these three categories as a foundation, box 1 gives a framework for understanding HAART treatment readiness.

    Box 1: Readiness to start drug treatment

    Before starting

    Basic

    • Basic knowledge of HIV transmission and prevention

    • Understanding of antiretroviral treatment, the side effects of treatment, and belief in treatment efficacy

    • Ability to comprehend, cope, and comply with prescribed actions, such as treatment adherence and safer sexual practices

    • Willingness to create support systems to cope with HIV status and facilitate treatment, such as disclosing status to family, friends, and partners

    After starting

    Functional

    • Advanced knowledge and skills to cope and manage HIV status and treatment that is grounded on experiences

    • Ability to recognise and seek care for opportunistic infections

    Critical

    • Considerable level of knowledge, personal autonomy, skills, and confidence to manage the consequences of HIV status and treatment

    • Capacity to take action that encourages health and discourages the determinants of ill health, such as substance abuse, unsafe sexual practice, and adherence

    In box 1, we have distinguished between the minimum readiness before starting treatment (basic) and the levels of readiness that may result from having treatment (functional and critical readiness). Readiness is also likely to be influenced by personal and social factors. For example, someone who has the support of family or friends and the personal drive to participate in treatment, but who does not have the basic information to start treatment, will have a different set of needs before becoming ready than someone who may have the information but lacks personal will and social support to participate in treatment. In this context, preparing the person with the information deficit is less challenging. In other words, what constitutes readiness for starting treatment should take all of these elements into account. Although we have given a somewhat polarised example, there can be different levels of knowledge, personal initiative, social support, etc. The readiness required to start treatment is also likely to be different from the readiness required to maintain successful participation in antiretroviral treatment programmes in an individual's lifetime. In addition, interactions with patients and care givers may also affect thinking and action about readiness—and, more importantly, the interface between patients and care givers is likely to influence whether patients maintain long term readiness for HAART after starting. The process of building patients' readiness, therefore, must be supportive and encouraging.

    After participation in a drug-readiness programme, patients should fulfil at least the criteria listed under basic readiness. The functional and critical levels of readiness may precede starting treatment or may be attained at various points in the course of treatment and will vary among people, but every effort should be made to move people forward through active collaboration with community organisations, non-state run programmes, and other sources of support.

    Box 2 shows the factors that constitute basic treatment readiness. Based on factors that have been used to assess readiness for behavioural changes, readiness for HIV treatment may include an understanding of the need for treatment, drive to live, and knowledge and capacity to maintain and build on commitment.1315 Personal responsibilities over these categories may differ by sex and age group, but what constitutes readiness should remain consistent. Children and young adolescents or adults with mental disabilities may not completely understand the consequences of their illness or the expected commitment required for treatment initiation and maintenance and will therefore require a care giver to support them during treatment. Care providers of HIV infected children should, therefore, participate in the drug readiness programme. Adolescents may or may not require a care giver or parent to participate for them to enrol in treatment, although it would be more beneficial.

    Can readiness to start HAART be measured?

    To date, a few small studies have measured readiness to start treatment using MEMS (medication event monitoring systems).16 This strategy has use for measuring drug adherence but is inadequate for assessing the broader concept of readiness. Experience garnered in assessing readiness in substance abuse treatment programmes,1720 despite considerable differences between the needs of the people in such programmes and patients starting HIV treatment, gives some important principles for assessing readiness for HIV treatment. Both groups, for example, face challenges with incorporating life changes and coping with their diagnosis that require high levels of long term commitment for success. Substance misuse programmes have used psychometric assessment scores to assess readiness. Based on basic readiness for treatment with antiretrovirals, as outlined in box 2, it is feasible to develop and test the reliability of psychometric measures. Importantly, operational research that monitors and measures the relationship between readiness and treatment outcomes is critical.

    Box 2: Basic readiness

    Need

    The person initiating treatment must understand that treatment can extend health and productive life. The participants must trust that treatment will be helpful. This is one of the factors that could be bolstered by experience on treatment.

    Drive to live

    This desire may be supported or discouraged by other aspects in life (family, children, partners, and friends). A component of the drive to live should include an assessment of shame, stigma, and how perceived or experienced discrimination is a force in the person's life. Understanding a person's drive to live may be guided by their expressions of fear for death. Within this context, assessing the presence and magnitude of anger, depression, and other emotionally distressing elements could be useful.

    Capacity

    Knowledge about HIV prevention and transmission and basic knowledge about the process of treatment and how treatment works, including side effects, is essential. A basic understanding that treatment works by “reducing the virus” in the body and the need to maintain viral suppression. Patients should understand the importance of adherence to treatment and safe sexual practice. Patients need confidence in their ability to meet expectations of commitment to treatment, including the coping strategies to maintain emotional stability.

    Summary points

    No clarity or consensus exists on what constitutes patients' readiness for HIV treatment and how readiness should be assessed

    The more established and readily measurable criteria currently used in decisions to start highly active antiretroviral treatment (HAART) need to be expanded

    Understanding the use of treatment readiness is particularly critical in settings where its role in initiating therapy may be misused to ration resources

    As the World Health Organization and UNAIDS's “3 by 5” initiative takes shape (to give three million people with HIV/AIDS in low and middle income countries antiretroviral treatment by the end of 2005), and as nations with limited resources increase access to HIV treatment, understanding and measuring readiness may become useful for HIV prevention and treatment outcomes. However, countries should be cautious about using readiness to ration access to treatment. Importantly, the assessment of readiness needs to be viewed as a process to advance all patients to a level of readiness that will support starting treatment and ensure equitable access to therapy. Developing sound criteria without restricting access to treatment is a challenging task that is integrally linked to the definition and measurement of readiness for treatment. The South African plan gives a valuable point of departure beyond the existing anecdotal notions that readiness is important in determining when to start HAART. We have presented a potential way forward in understanding how to construct, measure, and unpack the potential benefits of readiness for HIV prevention and treatment outcomes, but rigorous tools are required to assess various constructs of readiness.

    Acknowledgments

    We thank Motshedisi Sebitloane, department of medicine at the University of KwaZulu-Natal, and Jerome Singh, Centre for AIDS Programme of Research in South Africa.

    Footnotes

    • Contributors and sources The idea for the manuscript grew out of collaborative discussions on patient and provider challenges facing the South African HAART rollout plan. HTG searched the literature and drafted and revised the manuscript. KPM and QAK contributed to drafting and revising the manuscript. QAK gave additional guidance and direction for the paper. HTG is guarantor.

    • Funding National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services (1U19AI51794), and Research Supplement for Under-represented Minorities to the Brown/Tufts/Lifespan, Center for AIDS Research, Brown University, Providence, Rhode Island (P30 AI42853-05S1).

    • Competing interests None declared.

    References